Last updated: September 2, 2026
Deutetrabenazine, marketed by Teva Pharmaceuticals as Austedo and Austedo XR, has become one of Teva’s highest-value growth products. Revenue rose from approximately $555 million in 2021 to about $1.2 billion in 2023, driven by expanded use in tardive dyskinesia, Huntington’s disease chorea, and the launch of once-daily Austedo XR. The drug has a durable commercial position through brand momentum, differentiated dosing, and a layered patent estate, although long-term risk will depend on Orange Book challenges, competing VMAT2 inhibitors, and the timing of generic entry. [1][2]
What is deutetrabenazine and how does Austedo work?
Deutetrabenazine is a deuterated form of tetrabenazine that inhibits vesicular monoamine transporter 2, or VMAT2. By reducing presynaptic dopamine storage and release, it decreases involuntary movements associated with tardive dyskinesia and Huntington’s disease chorea.
Teva sells two oral formulations:
| Product |
Dosage form |
FDA status |
Principal uses |
| Austedo |
Twice-daily tablets |
Approved in 2017 |
Huntington’s disease chorea; tardive dyskinesia |
| Austedo XR |
Once-daily extended-release tablets |
Approved in 2023 |
Huntington’s disease chorea; tardive dyskinesia |
The immediate-release product requires divided dosing. Austedo XR offers once-daily administration, which supports adherence and gives Teva a lifecycle-management product with potentially stronger patient and prescriber retention. [3][4]
Deutetrabenazine carries warnings and precautions relating to depression and suicidality in patients with Huntington’s disease, neuroleptic malignant syndrome, akathisia, parkinsonism, sedation, QT prolongation, and interactions involving CYP2D6 metabolism. The label limits dosing in patients who are poor CYP2D6 metabolizers or who receive strong CYP2D6 inhibitors. [3]
How large is the deutetrabenazine market?
The addressable market is concentrated in two chronic neurologic conditions:
- Tardive dyskinesia, which develops after exposure to dopamine-receptor-blocking medicines, particularly antipsychotics.
- Huntington’s disease chorea, a smaller but high-need indication.
Tardive dyskinesia is the primary commercial driver. Patients may remain on treatment for years because the underlying exposure to antipsychotics often continues. The market therefore has recurring prescription economics rather than a short-course treatment profile.
The main branded competitor is valbenazine, marketed by Neurocrine Biosciences as Ingrezza. Generic tetrabenazine remains available but has a less convenient dosing profile and lacks the deuterated product’s pharmacokinetic positioning.
| Drug |
Company |
Main indications |
Dosing profile |
Commercial position |
| Austedo/Austedo XR |
Teva |
Tardive dyskinesia; Huntington’s chorea |
Twice daily or once daily XR |
Major VMAT2 product |
| Ingrezza |
Neurocrine |
Tardive dyskinesia; Huntington’s chorea |
Once daily |
Leading direct competitor |
| Xenazine/generic tetrabenazine |
Various |
Huntington’s chorea; some off-label movement-disorder use |
Multiple daily doses |
Lower-cost alternative |
Ingrezza is the closest competitive benchmark. Both branded products have expanded beyond Huntington’s disease into the larger tardive dyskinesia market. Their competition centers on payer access, specialty pharmacy distribution, titration, tolerability, dosing convenience, and field-force support rather than major differences in mechanism.
What has been the financial trajectory for Austedo?
Austedo has moved from a specialty product into a core Teva growth asset. Approximate annual net revenues reported by Teva were:
| Year |
Austedo revenue |
Approximate growth |
| 2021 |
$555 million |
N/A |
| 2022 |
$843 million |
52% |
| 2023 |
$1.2 billion |
Approximately 40% |
| 2024 |
Approximately $1.5 billion |
Approximately 25% |
Teva’s annual reports identify Austedo as a principal growth driver. Revenue expansion has reflected increased diagnosed and treated tardive dyskinesia patients, higher prescription volume, expanded market access, and adoption of the extended-release formulation. [1][2]
Austedo is strategically important because Teva remains heavily exposed to U.S. generic-price erosion and legacy product declines. A branded specialty product with strong growth and high gross margins improves the company’s product mix and provides an earnings counterweight to commoditized generic medicines.
What is Teva’s revenue exposure to deutetrabenazine?
At approximately $1.5 billion in annual sales, Austedo accounts for roughly 9% of Teva’s total revenue based on Teva’s 2024 company revenue of approximately $16.5 billion. The percentage is material for a single product and increases the financial consequences of a patent challenge or competing-product loss.
The exposure is larger when measured against Teva’s branded innovative-pharmaceutical portfolio rather than total company revenue. A sustained decline in Austedo would affect:
- U.S. specialty-pharmaceutical growth;
- operating-margin mix;
- investor expectations for Teva’s branded pipeline;
- debt-reduction capacity;
- valuation support for the company’s innovative-medicines segment.
The product is not yet a majority of Teva’s revenue, but it is one of the company’s most visible growth assets.
When does Austedo lose exclusivity?
Austedo’s regulatory exclusivity and patent exclusivity are separate.
The five-year new chemical entity exclusivity period associated with the original 2017 approval would have expired in 2022, subject to the regulatory classification of the active ingredient and approval protections. Orphan-drug exclusivity for Huntington’s disease chorea provides a separate seven-year protection period for that indication, but it does not block all products containing the same active ingredient for other uses. The principal long-term barrier is therefore the patent estate rather than remaining NCE exclusivity. [3][5]
Austedo XR, approved in 2023, did not create a new five-year NCE period for deutetrabenazine. It may receive limited three-year exclusivity for qualifying new clinical investigations supporting the supplemental approval, but that protection is narrower than patent protection and does not generally prevent approval of an ANDA for the original immediate-release product. [5]
What patents protect Austedo?
The Austedo patent estate includes patents directed to deuterated tetrabenazine compounds, pharmaceutical compositions, dosing regimens, and methods of treating movement disorders. Public Orange Book listings have included patents such as:
| Patent family or patent |
General subject matter |
Reported patent-term profile |
| U.S. Patent No. 8,815,847 |
Deuterated tetrabenazine compounds and related compositions |
Mid-2030s, subject to term adjustments |
| U.S. Patent No. 9,730,881 |
Deutetrabenazine compositions and therapeutic use |
Mid-2030s |
| U.S. Patent No. 10,478,455 |
Pharmaceutical compositions and dosing-related protection |
Late 2030s |
| U.S. Patent No. 10,583,138 |
Formulation or therapeutic-use protection |
Late 2030s |
| Later Teva patents |
Additional formulations, doses, and methods of use |
Potentially extending into the early 2040s |
Exact enforceable dates depend on patent-term adjustment, patent-term extension, terminal disclaimers, pediatric exclusivity, claim scope, and the specific product code or formulation. The Orange Book remains the controlling source for listed patents and current expiration information. [6]
The estate appears stronger than a single composition-of-matter patent because it contains multiple potential barriers. A generic applicant may be able to challenge one patent while remaining blocked by others, particularly if the ANDA proposes a different strength, release profile, or labeling strategy.
What formulations are protected by Austedo patents?
The commercial lifecycle is divided between immediate-release Austedo and once-daily Austedo XR.
Potentially relevant protection areas include:
- deuterated tetrabenazine compositions;
- specific ratios or stereochemical forms;
- dosage strengths;
- immediate-release tablets;
- extended-release tablets;
- once-daily dosing;
- treatment of tardive dyskinesia;
- treatment of Huntington’s disease chorea;
- dose escalation and maintenance regimens.
The most commercially important distinction is formulation. An ANDA applicant targeting the twice-daily tablets may face a different patent set from an applicant seeking to copy Austedo XR. Teva can also use formulation patents and method-of-use patents to complicate a full-substitution strategy even if a generic product ultimately reaches the market for one dosage form.
Which companies are challenging Austedo patents?
Publicly disclosed patent litigation and Paragraph IV activity should be evaluated at the patent-and-defendant level. Generic companies commonly targeted in Austedo-related proceedings include firms such as Apotex, Aurobindo, Lupin, Sun Pharmaceutical, and Zydus, although the active defendant list and litigation posture can change as cases settle, are dismissed, or are consolidated.
A Paragraph IV certification asserts that an Orange Book patent is invalid, unenforceable, or will not be infringed by the proposed generic. If the brand owner files an infringement action within 45 days of receiving notice, FDA approval of the ANDA can be stayed for up to 30 months, subject to statutory exceptions and court developments. [7]
The key commercial issue is whether the generic applicant challenges:
- The core compound patent;
- A formulation patent;
- A method-of-use patent;
- A dosing patent;
- All listed patents through multiple certifications.
A challenge limited to a narrow indication may support an earlier skinny-label launch. A broad Paragraph IV challenge creates more litigation risk but offers a greater potential reward if the generic applicant secures an early entry date.
What is the Orange Book status of Austedo?
Austedo is an FDA-approved prescription drug with listed patents in the Orange Book. The Orange Book identifies patents and exclusivity associated with approved products, but it does not determine whether a patent is valid or infringed.
For market forecasting, the relevant Orange Book questions are:
- Which patents are listed against immediate-release Austedo?
- Which patents are listed against Austedo XR?
- What are the expiration dates after patent-term adjustment?
- Have pediatric extensions been added?
- Has Teva delisted or amended any patent?
- Which ANDA applicants have submitted Paragraph IV certifications?
- Has a 30-month stay been triggered?
A product may have a long nominal patent expiration date but still face earlier entry through settlement, an at-risk launch, a successful validity challenge, or a non-infringing alternative formulation.
How strong is the deutetrabenazine patent estate?
The estate is commercially strong but not invulnerable.
Strengths
- Deutetrabenazine is a differentiated active ingredient rather than a conventional generic formulation.
- Teva has several patent families covering more than one technical feature.
- The product has both immediate-release and extended-release presentations.
- Tardive dyskinesia treatment methods can support claim strategies beyond the composition itself.
- The high value of the U.S. market gives Teva a strong incentive to litigate.
Vulnerabilities
- The underlying tetrabenazine pharmacology is established.
- Generic applicants can attack obviousness and written-description issues involving deuteration.
- Method-of-use patents can be vulnerable where the disease indication or dosing concept is clinically predictable.
- A successful challenge to a core compound patent would reduce the practical value of later, narrower patents.
- Ingrezza gives payers and prescribers a branded substitute before generic entry.
The strongest commercial defense is likely the combination of composition, formulation, and labeling protection. A patent estate that depends only on method-of-use claims would present a weaker barrier.
What generic entry risks exist for Austedo?
Generic entry is unlikely to be a single event. It could occur in stages:
| Scenario |
Timing logic |
Market impact |
| Settlement with an agreed future date |
Contractual entry date |
Predictable erosion, often gradual |
| Successful Paragraph IV challenge |
Court invalidates or narrows key patents |
Potentially rapid price and share erosion |
| Skinny-label launch |
Generic omits a protected indication |
Partial substitution |
| At-risk launch |
Generic enters before final resolution |
High litigation exposure and possible damages |
| XR-specific challenge |
Targets once-daily formulation |
Delayed but strategically important erosion |
| Authorized generic |
Teva or partner launches a licensed copy |
Greater control over price erosion |
Immediate-release generic competition would likely pressure net price, payer reimbursement, and patient assistance economics. Austedo XR could preserve a portion of the franchise if its patents remain enforceable and prescribers value once-daily dosing. The degree of substitution would depend on whether pharmacies can automatically substitute the generic for the branded formulation and whether the generic matches the same release profile.
How does Austedo compare with Ingrezza?
Austedo and Ingrezza have similar commercial targets but different competitive positions.
| Factor |
Austedo |
Ingrezza |
| Company |
Teva |
Neurocrine Biosciences |
| Active ingredient |
Deutetrabenazine |
Valbenazine |
| Tardive dyskinesia |
Approved |
Approved |
| Huntington’s chorea |
Approved |
Approved |
| Extended-release strategy |
Austedo XR |
Once-daily Ingrezza formulation |
| Primary commercial issue |
Teva’s access and sales execution |
Neurocrine’s category leadership |
| Generic risk |
Patent and ANDA challenges |
Separate valbenazine patent estate |
Ingrezza has generally held a strong position in tardive dyskinesia, while Austedo has used pricing, sales execution, and the XR formulation to expand share. The products compete in the same specialist channels, including psychiatry, neurology, long-term care, and specialty pharmacy.
The category is likely to grow before generic entry because diagnosis remains incomplete and many patients treated with antipsychotics are not systematically screened for tardive dyskinesia. Market expansion therefore depends on detection and treatment initiation, not only switching between brands.
What licensing deals support deutetrabenazine commercialization?
Teva acquired Auspex Pharmaceuticals in 2015 for approximately $3.5 billion, obtaining deutetrabenazine and Auspex’s deuterated-drug platform. The transaction transferred development and commercialization control to Teva. [8]
The acquisition explains why deutetrabenazine is strategically important to Teva. It was not an internally discovered generic-line extension. It was acquired as a specialty innovator asset and later developed across two movement-disorder indications and multiple formulations.
No external commercialization partner has the same strategic role as Teva in the U.S. Austedo business. Any later distribution or co-promotion arrangements would need to be distinguished from the core ownership and commercialization rights obtained through the Auspex transaction.
What is the FDA regulatory status of deutetrabenazine?
The FDA approved Austedo in April 2017 for chorea associated with Huntington’s disease and tardive dyskinesia. The FDA approved Austedo XR in August 2023 as an extended-release formulation for the same disease areas. [3][4]
The regulatory platform is mature. The central regulatory risks are postmarketing safety, label restrictions, manufacturing consistency, and any supplemental applications intended to expand the label or improve dosing.
No biosimilar pathway applies because deutetrabenazine is a small-molecule drug, not a biologic. Competition will arise through ANDAs and conventional Hatch-Waxman litigation rather than biosimilar applications.
What is the outlook for deutetrabenazine through generic entry?
The near- to medium-term outlook remains positive if Teva sustains patient additions and converts users to Austedo XR. Revenue growth should moderate from the rapid expansion recorded between 2021 and 2023 as the treated population becomes larger and competition from Ingrezza intensifies.
The principal value drivers are:
- continued expansion of tardive dyskinesia diagnosis;
- durable reimbursement and specialty-pharmacy access;
- conversion from immediate-release Austedo to Austedo XR;
- retention of Huntington’s disease patients;
- successful defense or settlement of Orange Book patents;
- limited substitution from generic tetrabenazine;
- absence of major safety restrictions.
The principal downside drivers are:
- early generic entry;
- invalidation of a core patent;
- aggressive pricing by Ingrezza;
- payer preference for the competing product;
- lower XR conversion than expected;
- safety-related reductions in prescribing;
- settlement terms that permit multiple generic entrants.
Austedo is likely to remain a major Teva revenue contributor until a generic or settlement-based entry event changes the market structure. The product’s financial trajectory is therefore more sensitive to patent litigation and competitive share than to FDA approval risk.
Key Takeaways
- Deutetrabenazine is Teva’s Austedo franchise, including twice-daily Austedo and once-daily Austedo XR.
- Revenue increased from approximately $555 million in 2021 to roughly $1.5 billion in 2024.
- Tardive dyskinesia is the principal growth market; Huntington’s disease chorea is smaller but supports durable specialty demand.
- Teva acquired the asset through its approximately $3.5 billion acquisition of Auspex Pharmaceuticals in 2015.
- Original NCE exclusivity has expired or is no longer the primary barrier. Patent protection and litigation now determine generic timing.
- The patent estate covers compounds, formulations, dosing, and methods of use, with listed patents extending into the 2030s and potentially early 2040s depending on the patent and applicable adjustments.
- Ingrezza is the principal branded competitor. Generic tetrabenazine is a lower-cost but less convenient alternative.
- Austedo has no biosimilar risk because deutetrabenazine is a small molecule.
- Generic entry could occur through settlement, a successful Paragraph IV challenge, a skinny-label product, or a formulation-specific launch.
- Austedo is financially material to Teva, accounting for approximately 9% of total company revenue at 2024 sales levels.
FAQs
Is deutetrabenazine the same as tetrabenazine?
No. Deutetrabenazine is a deuterated derivative of tetrabenazine. It has the same broad VMAT2-inhibitor mechanism but is a distinct active ingredient with different pharmacokinetic properties and its own regulatory and patent position.
Can a generic replace Austedo XR automatically?
Only if the generic is approved as therapeutically equivalent to the same extended-release product and is listed as substitutable under applicable state pharmacy rules. An immediate-release generic would not automatically substitute for Austedo XR.
Does Austedo have orphan-drug exclusivity?
Austedo received orphan-drug protection for its Huntington’s disease chorea indication. Orphan exclusivity is indication-specific and does not provide a blanket seven-year prohibition against all products containing deutetrabenazine.
Which drug is stronger commercially, Austedo or Ingrezza?
Ingrezza has been a leading product in tardive dyskinesia, while Austedo has achieved substantial growth through Teva’s commercial scale and the Austedo XR launch. Relative strength depends on market share, payer access, net price, and patient persistence by period.
What is the largest investment risk associated with deutetrabenazine?
The largest risk is earlier-than-expected generic entry following Paragraph IV litigation or a settlement. Because Austedo is one of Teva’s largest growth products, accelerated erosion would have a material effect on revenue mix and earnings expectations.
References
-
Teva Pharmaceutical Industries Ltd. (2024). Annual report on Form 20-F for the year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
Teva Pharmaceutical Industries Ltd. (2025). Annual report on Form 20-F for the year ended December 31, 2024. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2023). Austedo (deutetrabenazine) prescribing information.
-
U.S. Food and Drug Administration. (2023). FDA approves once-daily AUSTEDO XR for tardive dyskinesia and chorea associated with Huntington’s disease.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
-
U.S. Patent and Trademark Office. (2024). Patent Center and patent-term information for U.S. patents covering deutetrabenazine products.
-
U.S. Food and Drug Administration. (2024). ANDA submissions: Paragraph IV certifications and 30-month stay provisions.
-
Teva Pharmaceutical Industries Ltd. (2015). Teva to acquire Auspex Pharmaceuticals. Company transaction announcement.
